Biogen Inc.

Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program.

prnewswire.com - 2026-07-16 07:47:00

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

zacks.com - 2026-07-15 11:55:43

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen's global legal and compliance functions.

globenewswire.com - 2026-07-15 08:15:00

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript

seekingalpha.com - 2026-07-14 17:29:08

Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern.

marketbeat.com - 2026-07-14 15:02:25

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

zacks.com - 2026-07-14 13:16:05

Stocks are cautiously higher midday, as cooler inflation helps investors forget about higher oil prices

schaeffersresearch.com - 2026-07-14 12:03:00

LEQEMBIÂ Real-World LEADER Study Presented at AAICÂ 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable a

gurufocus.com - 2026-07-14 12:00:00

Biogen Inc. (NASDAQ:BIIB) on Tuesday said it will advance investigational Alzheimer's therapy diranersen into Phase 3 testing after new Phase 2 data showed the tau-targeting treatment slowed clinical decline while producing significant biomarker reductions.

benzinga.com - 2026-07-14 11:49:02

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Mass., July 14, 2026 /PRNewswire/ -- Eisai Co., Ltd.

prnewswire.com - 2026-07-14 11:15:00

The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a midstage ​trial, reduced cognitive decline in five of six Alzheimer's assessment tools and significantly cut levels of the toxic protein in the brain, researchers ‌reported on Tuesday.

reuters.com - 2026-07-14 09:18:47

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. The data, presented at the Alzheimer's Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical effi.

businesswire.com - 2026-07-14 09:16:00

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.

investors.com - 2026-07-14 09:15:18

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. The data, presented at the Alzheimer's Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical efficacy and robust biomarker effects, providing Phase 2 proof of concept for diranersen's tau-directed mechanism of action. Based on the growing and consistent body of evidence from the Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.1

globenewswire.com - 2026-07-14 09:15:00

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 TOKYO and CAMBRIDGE, Mass., July 13, 2026 /PRNewswire/ -- Eisai Co., Ltd.

prnewswire.com - 2026-07-13 17:36:00

The U.S. FDA on Monday approved an ​at-home starting dose of Eisai's and Biogen's Alzheimer's drug, ‌allowing some patients to begin therapy with injections administered by themselves or a caregiver.

reuters.com - 2026-07-13 15:02:12

Energy names help cushion the Dow as oil jumps on U.S.-Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026.

fool.com - 2026-07-13 12:14:50

Biogen stock receives a bullish upgrade based on expectations the market will cheer the company's detailed data on its experimental Alzheimer's drug.

barrons.com - 2026-07-13 08:15:00

Futures are trading lower as we get ready for the start of second-quarter earnings this week, after a solid winning week on Wall Street.

247wallst.com - 2026-07-13 07:55:13

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

benzinga.com - 2026-07-13 07:07:24

LEQEMBIÂ Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented

gurufocus.com - 2026-07-12 12:00:00

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 /PRNewswire/ -- Eisai Co., Ltd.

prnewswire.com - 2026-07-12 11:15:00

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-07 13:11:06

Biogen struggled in recent years after a major blockbuster lost exclusivity. The company's new focus on growth is bearing fruit -- and the latest acquisition strengthens Biogen's position in the key area of immunology.

fool.com - 2026-07-04 04:02:00

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

zacks.com - 2026-07-01 10:05:15

BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.

zacks.com - 2026-06-30 06:11:06

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

zacks.com - 2026-06-29 12:11:05

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com - 2026-06-29 09:11:09

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Biogen, Inc. (NASDAQ: BIIB):   OKLAHOMA FIREFIGHTERS PENSION AND RETIREMENT SYSTEM,                                                        Plaintiff,                               v. BIOGEN INC.

globenewswire.com - 2026-06-29 08:00:00

CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London, UK. Presentations will include data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of LEQEMBI® (lecanemab).

globenewswire.com - 2026-06-29 06:59:00

Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs ​as it integrates the rare-disease drugs specialist it purchased ‌for $5.6 billion earlier this year.

reuters.com - 2026-06-26 09:25:41

Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.

zacks.com - 2026-06-26 09:21:05

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-25 10:00:00

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-23 17:58:00

Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.

feeds.benzinga.com - 2026-06-18 11:07:15

BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.

zacks.com - 2026-06-18 10:55:24

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-18 10:00:00

Biogen said on Wednesday it would acquire drug discovery company RayThera for $1 billion, including milestone payments.

reuters.com - 2026-06-17 19:10:57

Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 development Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 development

globenewswire.com - 2026-06-17 18:59:00

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-16 18:45:00

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

prnewswire.com - 2026-06-11 12:00:00

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-11 10:00:00

After not buying or selling any stocks in 2025, a congresswoman who made over $2.4 million in trades in 2024 is buying stocks once again in 2026. Here's a look at the latest transactions.

benzinga.com - 2026-06-10 18:46:27

LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

globenewswire.com - 2026-06-10 10:29:00

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-09 13:42:00

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

benzinga.com - 2026-06-08 09:58:05

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

prnewswire.com - 2026-06-08 09:00:00

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

zacks.com - 2026-06-05 13:05:19

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc

gurufocus.com - 2026-06-04 21:00:00